Low expression lncRNA RPLP0P2 is associated with poor prognosis and decreased cell proliferation and adhesion ability in lung adenocarcinoma.
We investigated the clinical roles and biological function of long non-coding (lncRNA) RPLP0P2 in lung adenocarcinoma (LAD). The expression level of RPLP0P2 was estimated by quantitative reverse transcription-polymerase chain reaction (qPCR) in 57 pairs of LAD and NT samples and the relation of RPLP0P2 to clinical data of LAD patients was analyzed. We overexpressed RPLP0P2 based on the human LAD cell line A549 by lentivirus‑mediated technology, then oncological behavior change was observed of A549 cells and the change of mRNA level of LRRC10B and RPLP0P2 by qPCR. We found that RPLP0P2 expression was lower while LRRC10B mRNA level was higher in LAD than NT by qPCR. RPLP0P2 expression level was negative correlated to LRRC10B mRNA level (Pearson correlation =‑0.754, P=0.0021). The expression of RPLP0P2 in lymph node metastasis of LAD group was significantly lower than LAD without lymph node metastasis group. Survival analysis showed that survival time of high expression of RPLP0P2 was significantly longer than low RPLP0P2 level in LAD patients. After RPLP0P2 was overexpressed, the proliferation rate, adhesion ability, S phase and G2/M phase cells and LRRC10B mRNA significantly reduced, while apoptosis and G0/G1 phase cells obviously increased, but migration ability and invasion did not significantly change. Our study ascertained that low expression of RPLP0P2 in LAD is associated with poor prognosis and decreased proliferation and adhesion ability of tumor cells. LRRC10B may be a downstream gene regulated by RPLP0P2.